Brief: Adaptimmune Reports data from Phase 2 SPEARHEAD-1 Trial At ASCO

Adaptimmune Therapeutics

19/05/2021 22:37

May 19 (Reuters) - Adaptimmune Therapeutics PLC  ADAP.O :
    * TWO COMPLETE RESPONSES AND RESPONSE RATE OF 41% FOR PEOPLE
WITH
SYNOVIAL SARCOMA REPORTED AT ASCO IN ADAPTIMMUNE’S PHASE 2
SPEARHEAD-1 TRIAL
    * ADAPTIMMUNE THERAPEUTICS PLC - DATA WILL SUPPORT BLA
FILING FOR
AFAMITRESGENE AUTOLEUCEL NEXT YEAR
    * ADAPTIMMUNE THERAPEUTICS PLC - AFAMI-CEL IS EFFICACIOUS
AND
WELL-TOLERATED IN HEAVILY PRE-TREATED PATIENTS BASED ON INITIAL
DATA
    * ADAPTIMMUNE THERAPEUTICS PLC - INITIAL SAFETY AND
DURABILITY
INITIAL DATA FROM ITS PHASE 2 SPEARHEAD-1 TRIAL ARE ENCOURAGING
    * ADAPTIMMUNE THERAPEUTICS PLC - RESPONSES OBSERVED ACROSS A
BROAD
RANGE OF ANTIGEN EXPRESSION

Source text for Eikon:  ID:nGNX67BxdV 
Further company coverage:  ADAP.O 

 ((Reuters.Briefs@thomsonreuters.com;))